Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial

Ann Rheum Dis. 2019 Oct;78(10):1439-1441. doi: 10.1136/annrheumdis-2019-215183. Epub 2019 Apr 24.

Authors

Kristen Sweet¹, Bidisha Dasgupta², Dick de Vries², Ian Gourley², Benjamin Hsu², Matthew J Loza³, Peter C Taylor⁴

Affiliations

¹ Janssen Research & Development, Spring House, Pennsylvania, USA.
² Janssen Research & Development, Ambler, Pennsylvania, USA.
³ Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
⁴ Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK peter.taylor@kennedy.ox.ac.uk.

PMID: 31018960
DOI: 10.1136/annrheumdis-2019-215183

No abstract available

Keywords: dmards (biologic); rheumatoid arthritis; ultrasonography.

Publication types

Clinical Trial, Phase III
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab / therapeutic use*
Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / diagnostic imaging*
Arthritis, Rheumatoid / drug therapy
Arthritis, Rheumatoid / pathology
Female
Humans
Joints / blood supply*
Joints / diagnostic imaging
Male
Middle Aged
Neovascularization, Pathologic / diagnostic imaging
Severity of Illness Index
Ultrasonography, Doppler / statistics & numerical data*

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
sirukumab
Adalimumab